The use of deoxypeganin hydrochloride in the combined treatment of patients with diseases of the peripheral nervous system

Paper

The use of deoxypeganin hydrochloride in the combined treatment of patients with diseases of the peripheral nervous system

Published Mar 1, 1989 · Tarasiuk Vk, Timko Na, Guba Gp

Vrachebnoe delo

UNKNOWN SJR score

2

Citations

0

Influential Citations

Semantic Scholar

Abstract

: A study is presented of the efficacy of 1% deoxypeganin hydrochloride solution in muscle lesions due to involvement of the peripheral nervous system in 19 patients in whom the drug was administered into the motor points of the involved muscles. In 13 similar patients the drug was given intramuscularly. Clinical and electromyographic studies indicate that local use proved more effective than traditional.

Non-RCT

Study Snapshot

Local use of deoxypeganin hydrochloride in peripheral nervous system muscle lesions is more effective than intramuscular use, with clinical and electromyographic studies showing improved results.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

The use of deoxypeganin hydrochloride in the combined treatment of patients with diseases of the peripheral nervous system

Sign up to use Study Snapshot

References

Citations

Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses.

Desoxypeganine (DOP) has linear and dose-proportional pharmacokinetics, satisfactory oral bioavailability, plasma half-life, and renal excretion, and an adequate safety profile for further clinical development.